Trayodashang Guggulu
Preclinical
Trayodashang Guggulu is one of 15 therapeutic programs targeting Knee Osteoarthritis. It is currently in Preclinical.
2
Indications
1
Total Trials
1
Active Trials
14
Competitors
Pipeline
Status by Indication[2][1]
Competition
Competitive Landscape
14 competitors in Knee Osteoarthritis
#DrugCompanyPhaseTrials
1Cymbalta
Jazz PharmaceuticalsApproved
Inulin and Sodium Chloride
BBlue Earth Diagnostics
Phase 2
Surgicel
PPeking University Third Hospital
Phase 3
Medrol
PfizerPreclinical
Allocetra
EEnlivex Therapeutics Ltd.
Phase 2
Decadron
AAspen Global Incorporated
Preclinical
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Preclinical
Solu-Medrol
MMassachusetts Eye and Ear Infirmary
Preclinical
Paracetamol
GSKPreclinical
Bee Venom Phonophoresis
SSinai University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Knee Osteoarthritis (Knee OA)1 trial
Holistic Healing for Knee Osteoarthritis: Comparing Integrated, Standard Medical, and Ayurvedic Care
Not yet recruiting·AAll India Institute of Medical Sciences, Jodhpur·Preclinical·NCT07768709·300 enrolled
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Trayodashang Guggulu. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Preclinical[1]